<DOC>
	<DOCNO>NCT00121030</DOCNO>
	<brief_summary>The purpose study validate Patient Satisfaction Questionnaire Anemia Treatment ( PSQ-AT ) gynecological cancer patient treat darbepoetin alfa recombinant human erythropoietin ( rHuEPO ) anemia due chemotherapy .</brief_summary>
	<brief_title>Treatment Patients With Gynecological Malignancies Who Suffer From Anemia Due Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Subjects receive multicycle chemotherapy gynecological cancer Anemia due chemotherapy ( hgb less equal 11.0 g/dL ) Expected receive great equal 8 additional week chemotherapy part plan treatment Karnofsky Performance Scale ( KPS ) great equal 50 % Adequate renal function Adequate liver function Iron deficiency Known positive test human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>uterine cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>Amgen</keyword>
	<keyword>Gynecological Malignancies</keyword>
</DOC>